Physician profile
John Chapman
NPI 1437474772
$4,809.04
in general payments reported to CMS, 2019-2025
14 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2021: $309 · 2022: $686 · 2023: $667 · 2024: $1,585 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,276.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $981.38 | 2019-2025 | Ebglyss, Olumiant |
| Abbvie INC. | $875.27 | 2021-2024 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $506.84 | 2023-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $503.54 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $462.41 | 2019-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $378.46 | 2022-2025 | Dupixent |
| Amgen INC. | $288.54 | 2024 | Otezla, Actimmune |
| Pfizer INC. | $171.83 | 2019-2023 | |
| Bard Peripheral Vascular, INC. | $151.99 | 2025 | Venclose Maven Catheter |
| E.R. Squibb & Sons, L.L.C. | $138.73 | 2022-2023 | Sotyktu |
| Dermira, INC. | $105.95 | 2019 | |
| Leo Pharma INC. | $102.76 | 2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $96.34 | 2019 | |
| Kerecis Limited | $45.00 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.